Background: To date, there are no strict recommendations for realization screening preclinical researches to estimate effects of new drug candidates on the hemostasis system.

Aims: In this work has demonstrated opportunities of thromboelastography as a screening method for  remedies, which affecting the hemostasis system , for example 2×10^-3 M acetylsalicylic acid (Shandong Xinghua Pharmaceutical Co., LTD, China).

Methods: The research was approved by the ethics committee of Bashkir State Medical University (№2 от 17.10.2012). Informed consent was obtained from all study participants before blood sampling. Modeling hyperactivity of hemostasis system was carried out in vitro by the method of activated thromboelastography on the blood of healthy male donors (n = 100) aged 18-24 years. Thromboelastography was carried out on a TEG 5000 (Haemonetics Corp., Braintree, MA). As a TEG activator were used 0,2 М CaCl2, recombinant tissue factor (Innovin®, Dade Behring, Germany) and thrombin («Technologiya-Standart», Russia). In the analysis of thromboelastograms was determined the general tendency of coagulation (R), the functional activity of platelets and fibrinogen (MA, Angle), the activity of fibrinolysis (CLT), and the physicomechanical properties of the formed clots (G).

Results: The effect of aspirin is characterized by a significant decrease in the MA indicator. It is worth noting that the antiaggregatory activity of aspirin depends on the blood coagulation activator and is more effective when coagulation is activated by 0,2 М CaCl₂ compared with thrombin and tissue factor.

Conclusions: Thus, the possibilities of thromboelastography as a screening method of affecting new pharmacological agents on the hemostasis system at the preclinical research stage with the possibility of modeling diseases in which there is an excess of thrombin or tissue factor.

« Back to ISTH 2021 Congress

ISTH Congress Abstracts - https://abstracts.isth.org/abstract/the-role-of-thromboelastography-in-search-for-drug-candidates/